DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol

<p><strong>Objective:</strong> The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by comparing the frequency of adverse events...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Ana Hernández-Guío, M.ª Ángeles Bernabéu-Martínez, Andrés Corno-Caparrós, M.ª Teresa Aznar-Saliente, Manuel Bonete-Sánchez, Miguel Ángel Calleja-Hernández
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	Elsevier 2021-05-01
Σειρά:	Farmacia Hospitalaria
Θέματα:	clinical protocols precision medicine fluoropyrimidines pharmacogenetics toxicity genetic polymorphism dpyd dihydropyrimidine dehydrogenase
Διαθέσιμο Online:	http://www.aulamedica.es/fh/pdf/11607.pdf

Παρόμοια τεκμήρια

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
ανά: Jonathan E. Knikman, κ.ά.
Έκδοση: (2024-08-01)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
ανά: Chi C. Tong, κ.ά.
Έκδοση: (2018-07-01)

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol
ανά: Cassandra White, κ.ά.
Έκδοση: (2024-11-01)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
ανά: Paula Soria-Chacartegui, κ.ά.
Έκδοση: (2021-11-01)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
ανά: Nedal Bukhari, κ.ά.
Έκδοση: (2021-07-01)

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
ανά: Anna Malekkou, κ.ά.
Έκδοση: (2024-03-01)

Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine
ανά: Timur Cerić, κ.ά.
Έκδοση: (2010-05-01)

<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
ανά: Theodore J. Wigle, κ.ά.
Έκδοση: (2023-01-01)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
ανά: Angela Wu, κ.ά.
Έκδοση: (2023-09-01)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
ανά: David K. Lau, κ.ά.
Έκδοση: (2023-04-01)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
ανά: Jorge E. B. da Rocha, κ.ά.
Έκδοση: (2021-03-01)

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of <i>DPYD</i> Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study
ανά: Xando Díaz-Villamarín, κ.ά.
Έκδοση: (2024-07-01)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
ανά: Masashi Kanai, κ.ά.
Έκδοση: (2023-04-01)

<i>DPYD</i> and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
ανά: Theodore J. Wigle, κ.ά.
Έκδοση: (2019-05-01)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
ανά: Eiji Hishinuma, κ.ά.
Έκδοση: (2022-06-01)

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature
ανά: White C, κ.ά.
Έκδοση: (2021-12-01)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
ανά: Ursina B. M. Begré, κ.ά.
Έκδοση: (2022-05-01)

The Frequency of <i>DPYD</i> c.557A>G in the Dominican Population and Its Association with African Ancestry
ανά: Mariela Guevara, κ.ά.
Έκδοση: (2024-12-01)

Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines
ανά: Elena De Mattia, κ.ά.
Έκδοση: (2024-12-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
ανά: Georgia Ragia, κ.ά.
Έκδοση: (2023-09-01)

Near Miss or Standard of Care? <i>DPYD</i> Screening for Cancer Patients Receiving Fluorouracil
ανά: Lauren E. Winquist, κ.ά.
Έκδοση: (2020-12-01)

Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report
ανά: Deborah Mukherji, κ.ά.
Έκδοση: (2019-03-01)

Upfront <i>DPYD</i> Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
ανά: Antoine Desilets, κ.ά.
Έκδοση: (2022-01-01)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
ανά: Anthi Maslarinou, κ.ά.
Έκδοση: (2023-05-01)

Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients
ανά: Alessio Ardizzone, κ.ά.
Έκδοση: (2024-09-01)

Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics
ανά: Annalaura Montella, κ.ά.
Έκδοση: (2024-04-01)

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity
ανά: Emma eBorràs, κ.ά.
Έκδοση: (2013-01-01)

Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment
ανά: Ana Hernández-Guío, κ.ά.
Έκδοση: (2024-12-01)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
ανά: Raffaele Palmirotta, κ.ά.
Έκδοση: (2019-03-01)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
ανά: A. Bignucolo, κ.ά.
Έκδοση: (2023-05-01)

Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation
ανά: K. B. Mirzaev, κ.ά.
Έκδοση: (2020-09-01)

Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene
ανά: García-González X, κ.ά.
Έκδοση: (2018-10-01)

The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐FU in pancreatic cancer
ανά: Hiroyuki Kato, κ.ά.
Έκδοση: (2024-08-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
ανά: Seid Hamzic, κ.ά.
Έκδοση: (2020-11-01)

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing
ανά: Lisa A. Varughese, κ.ά.
Έκδοση: (2022-07-01)

ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study
ανά: Lennard Y. W. Lee, κ.ά.
Έκδοση: (2019-10-01)

Dihydropyrimidine dehydrogenase level and the redox status in patients with colorectal cancer are prognostic for adverse effects of fluoropyrimidines
ανά: Nadya G. Hristova-Avakumova, κ.ά.
Έκδοση: (2021-01-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
ανά: Linda Cucciniello, κ.ά.
Έκδοση: (2022-09-01)

Relationship Between Dihydropyrimidine Dehydrogenase Gene Polymorphism and Toxicities in Cancer Patients Receiving 5-Fluorouracil
ανά: Tahsin YÜKSEL, κ.ά.
Έκδοση: (2024-08-01)

Implementation of DPYD testing in Bulgarian patients with cancer
ανά: Nelly Miteva-Marcheva, κ.ά.
Έκδοση: (2024-12-01)